Business Context and Reporting Period
Company: Acacia Research Corporation (California Corporation)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 1996
Business Overview: The Company provides capital management services and makes direct investments in emerging corporations. Key portfolio companies include Whitewing Labs, Inc., MerkWerks Corporation, CombiMatrix Corporation, and Soundview Technologies Incorporated. The Company also acts as a general partner for private investment partnerships and an investment advisor for an offshore fund.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Total Revenues | $1,826,117 | $259,593 |
| Net Income | $883,499 | $(1,754) |
| Earnings Per Share (Diluted) | $0.33 | $(0.00) |
| Cash and Cash Equivalents | $873,375 | $102,223 |
| Working Capital | $2,599,412 | N/A |
| Net Cash from Operating Activities | $71,857 | $(8,430) |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased by $1,566,524 (603%) compared to Q1 1995. This was driven primarily by a non-cash unrealized gain of $1,066,408 resulting from the initial public offering (IPO) of affiliate Whitewing Labs, Inc., which increased the book value of the Company's retained interest.
- Profitability: The Company transitioned from a net loss of $1,754 in Q1 1995 to a net income of $883,499 in Q1 1996.
- Expense Growth: Marketing, general, and administrative expenses rose to $425,781 from $260,547, attributed to the costs of operating as a public company (legal, accounting, printing). However, as a percentage of revenue, expenses dropped from 100.4% to 23.3%.
- Liquidity: Cash and cash equivalents grew significantly from $102,223 to $873,375. The current ratio improved to 17.9 to 1.
- Accounting Restatement: Prior period financial statements were restated to reflect the change in accounting for the Whitewing Labs investment from consolidation to the equity method, reducing Q1 1995 EPS from $0.03 to $0.00.
Guidance, Outlook, and Risks
- Outlook: Management anticipates that cash generated from operations and working capital reserves will be adequate to fund recurring capital expenditures for fiscal 1996 and the foreseeable future. Collection of notes receivable is expected to provide cash flow in the second quarter.
- Future Gains: While no similar unrealized gains are anticipated from Whitewing Labs, management expects future gains of this nature from other subsidiaries when they become publicly offered entities.
- Risks and Contingencies:
- Concentration of Credit Risk: Notes receivable totaling $1,308,750 are due from two individuals. While collateralized by common stock and personally guaranteed, this represents a concentration risk.
- Bank Balances: As of March 31, 1996, the Company held $566,622 in bank balances in excess of insured amounts.
- Securities Sales: The timing and extent of sales of securities are subject to substantial fluctuation. The Company is currently prohibited from selling Whitewing Labs shares without consent until February 9, 1997.
Investor Verification Checklist
- Unrealized Gain Validity: Verify the $1,066,408 unrealized gain from the Whitewing Labs IPO and its impact on net income, as this is a non-cash item.
- Notes Receivable Quality: Confirm the collectability of the $1,489,751 in notes receivable, particularly the $1,308,750 concentrated in two individuals, and the value of the collateral securing them.
- Equity Method Investments: Review the financial health of unconsolidated subsidiaries (Whitewing Labs, CombiMatrix, Acacia Capital Partners) as the Company's earnings are heavily dependent on equity in earnings of these investments.
- Stock Subscription Receivables: Monitor the collection of the $203,002 stock subscription receivable, which is deducted from stockholders' equity.
- Deferred Tax Assets: Assess the realizability of the $1,002,594 deferred tax asset related to nonstatutory stock options.